GSK gets court to block patent rules

Score one for GlaxoSmithKline. The company won an injunction against the U.S. Patent and Trademark Office, successfully blocking implementation of new rules governing patent continuances, at least temporarily.

GSK will now ask the court to permanently scrap the rules, which were set to go into effect today. The rules would have reduced the number of times a patent holder could dicker with rejected or pending patent, and GSK claimed they would hamstring innovation.

- read the report from Interactive Investor
- see this WSJ item

Related Articles:
GSK sues over new patent rules. Report
Standards on biotech patents get tougher. Report
Behind the scenes of GSK's overhaul. Report
GSK plant closure begins 5,000 job cuts. Report
Glaxo to cut $1.4B on falling sales. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.